Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Bengaluru: Merck is reportedly in talks to acquire lung disease-focused biotech Verona Pharma in a deal worth nearly USD 10 ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Insmed said on Tuesday that its experimental drug significantly reduced blood pressure in the lungs and improved exercise capacity in patients in a mid-stage study, lifting its shares up as much ...

Pharmalittle: We’re reading about FDA chaos delaying a rare disease drug, Merck’s U.S. investment, and more Novo Nordisk strikes telehealth deals to expand efforts to sell Wegovy directly to ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.